• JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
 
  Bookmark and Share
 
 
Doctoral Thesis
DOI
https://doi.org/10.11606/T.87.2009.tde-22122009-115959
Document
Author
Full name
Flávia Serpieri
Institute/School/College
Knowledge Area
Date of Defense
Published
São Paulo, 2009
Supervisor
Committee
Moro, Ana Maria (President)
Brigido, Marcelo de Macedo
Kalil Filho, Jorge Elias
Soares, Carlos Roberto Jorge
Tavassi, Ana Marisa Chudzinski
Title in Portuguese
Geração de linhagens de células CHO transfectadas com vetores para expressão de anticorpos monoclonais humanizados anti-determinantes leucocitários: anti-CD3 e anti-CD18.
Keywords in Portuguese
Amplificação gênica
Anticorpos monoclonais (Humano)
Biotecnologia
Células CHO
Expressão estável
FvFc
Recombinação homóloga
Abstract in Portuguese
O projeto de obtenção de huAcMos (Anticorpos Monoclonais Humanizados) tinha como escopo a humanização de anticorpos murinos com potencial terapêutico, inserção das sequências em vetores de expressão e transfecção em células CHO (do inglês, Chinese Hamster Ovary). A expressão do huAcMo Anti-CD18 resultou em baixos níveis da proteína recombinante e inciamos o processo de expressão de isoformas do huAcMo Anti-CD3. As células foram transfectadas com seqüências codificadoras do fragmento FvFc Anti-CD3 e clonadas pelo equipamento ClonePix FL. O fragmento foi caracterizado e demonstrou uma menor afinidade quando comparada com a molécula murina original. Ulizamos o sistema de recombinação homóloga (CHO Flp-In, Invitrogen) para expressão da molécula inteira do huAcMo Anti-CD3. Os clones foram caracterizados e demonstrou, assim como o fragmento FvFc, uma menor afinidade pelo alvo. As diferenças nas propriedades de ligação são freqüentemente encontradas após processos de humanização; dependendo da função efetora esta diminuição de afinidade não é negativa para a molécula.
Title in English
Generation of CHO cell lines expressing humanized monoclonal antibodies anti-leukocytary determinants: anti-CD3 and anti-CD18.
Keywords in English
Biotechnology
CHO cells
FvFc
Genetic amplification
Homologous recombination
Monoclonal antibodies (Human)
Stable expression
Abstract in English
The humanized antibodies (huMab) project intent to use murine antibodies with therapeutic potencial to obtain more human sequences with maintened specificity. The sequences were inserted in expression vectors and transfected in CHO (Chinese Hamster Ovary) cells. Anti-CD18 huMab expression results in low levels of recombinant protein and lead us to try the expression of Anti-CD3 isoforms. The cells were transfected for the expression of a FvFc antibody fragment and cloned using ClonePix FL equipment. The fragment characterization demonstrate a lower affinity when compared with the murine molecule. We use the homologous recombination system (CHO Flp-In) for the expression of the whole molecule of huMab Anti-CD3; like the FvFc fragment, the whole molecule demonstrate a lower affinity for the target. The differences in the affinity properties are frequently found after humanization process and depending on the expected efector functions is not negatively characterized.
 
WARNING - Viewing this document is conditioned on your acceptance of the following terms of use:
This document is only for private use for research and teaching activities. Reproduction for commercial use is forbidden. This rights cover the whole data about this document as well as its contents. Any uses or copies of this document in whole or in part must include the author's name.
Publishing Date
2010-02-23
 
WARNING: Learn what derived works are clicking here.
All rights of the thesis/dissertation are from the authors
CeTI-SC/STI
Digital Library of Theses and Dissertations of USP. Copyright © 2001-2024. All rights reserved.